Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions

Study Overview
=================
Brief Summary
-----------------
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers under Fasting Conditions

Detailed Description
-----------------
A randomized, open-label, single dose, crossover study to investigate the pharmacokinetic profiles and safety of high-dose CKD-385 in healthy volunteers under fasting conditions

Official Title
-----------------
A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers Under Fasting Conditions

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Drug: Reference drug
* Drug: Test drug 1
* Drug: Test drug 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult aged more than 19 at the time of screening Those who had 18.0kg/m² ≤ Body Mass Index (BMI) < 30.0kg/m² # BMI=Weight(kg) / Height(m)² Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings on a medical examination. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, urinalysis, serology), vital signs and ECG results at screening. Those who have voluntarily given written informed consents to participate in the study and to comply with all the instructions, based on full understanding of the nature of the study after listening to detailed explanations. Those who agree to double contraception method from the 1st administration of the investigational product until 7 days after the last administration of investigational product. Exclusion Criteria: Those who has medical evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or allergic diseases(except for simple dental history such as tartar, impacted teeth, wisdom teeth). Those with a medical history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug. Those who has a history of regular alcohol consumption in excess of 14 glasses/week for woman, 21 glasses/week for man within 1 months prior to screening. Those who received investigational products or bioequivalence test drugs within 6 months before the first administration of clinical trial drugs. Those who take drugs which may cause induction or inhibition of drug metabolism within 30 days before the first administration of investigational products. Those who have taken any drugs that may affect the clinical trial within 10 days. Those who donated whole blood within 2 months, or blood components within 2 week before first administration of investigational products. Those who are deemed insufficient to participate in this clinical study by investigators.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1<br>Period 1: Reference drug Period 2: Test drug 1 Period 3: Test drug 2 | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|
| Experimental: Group 2<br>Period 1: Test drug 2 Period 2: Reference drug Period 3: Test drug 1 | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|
| Experimental: Group 3<br>Period 1: Test drug 1 Period 2: Test drug 2 Period 3: Reference drug | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|
| Experimental: Group 4<br>Period 1: Test drug 2 Period 2: Test drug 1 Period 3: Reference drug | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|
| Experimental: Group 5<br>Period 1: Test drug 1 Period 2: Reference drug Period 3: Test drug 2 | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|
| Experimental: Group 6<br>Period 1: Reference drug Period 2: Test drug 2 Period 3: Test drug 1 | Drug: Reference drug<br>* 1 Cap., single oral administration under fasting condition<br>* Other names: D744;Drug: Test drug 1<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);Drug: Test drug 2<br>* 1 Tab., single oral administration under fasting condition<br>* Other names: CKD-385 64 mg formulation I (878mg);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCt of CKD-385 | Area under the concentration-time curve from time zero to time of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 
| Cmax of CKD-385 | Maximum plasma concentration of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf of CKD-385 | Area under the concentration-time curve from zero up to infinity of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 
| Tmax of CKD-385 | Time to maximum plasma concentration of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 
| T1/2 of CKD-385 | Terminal elimination half-life of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 
| CL/F of CKD-385 | Apparent clearance of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours | 
| Vd/F of CKD-385 | Apparent Volume of Distribution of CKD-385 | Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours |